Yahoo
Frankfurt - Delayed Quote EUR

Thermo Fisher Scientific Inc. (TN8.F)

626.00 +5.60 (+0.90%)
As of 11:39:56 AM GMT+1. Market Open.
Chart Range Bar
Loading chart for TN8.F
  • Previous Close 620.40
  • Open 622.00
  • Bid 618.20 x 60000
  • Ask 626.80 x 60000
  • Day's Range 618.40 - 627.20
  • 52 Week Range 374.80 - 637.00
  • Volume 9
  • Avg. Volume 108
  • Market Cap (intraday) 231.943B
  • Beta (5Y Monthly) 0.88
  • PE Ratio (TTM) 38.43
  • EPS (TTM) 16.32
  • Earnings Date Oct 21, 2026
  • Forward Dividend & Yield 1.68 (0.27%)
  • Ex-Dividend Date Sep 15, 2026
  • 1y Target Est --

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

www.thermofisher.com

125,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TN8.F
26.72%
S&P 500 (^GSPC)
10.73%

1-Year Return

TN8.F
28.66%
S&P 500 (^GSPC)
10.82%

3-Year Return

TN8.F
50.97%
S&P 500 (^GSPC)
75.55%

5-Year Return

TN8.F
15.60%
S&P 500 (^GSPC)
63.69%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 12.14B
Earnings 1.72B
Profit Margin 14.18%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
6B
8B
10B
12B
14.5%
15.0%
15.5%
16.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.94%

  • Return on Assets (ttm)

    5.23%

  • Return on Equity (ttm)

    13.38%

  • Revenue (ttm)

    47.35B

  • Net Income Avi to Common (ttm)

    7.07B

  • Diluted EPS (ttm)

    16.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.06B

  • Total Debt/Equity (mrq)

    75.36%

  • Levered Free Cash Flow (ttm)

    6.45B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: